Abstract
Currently rational drug design is limited to using protein targets in the design and production of therapeutic agents. However, many genetic and infectious diseases may not be adequately treated with this approach. In these circumstances the DNA sequence of an offending gene is itself a potential target for rational drug development. Genetargeted therapeutic strategies require the development of ligands that can recognize and bind unique DNA targets sequence specifically. Several approaches have been described for the development of sequence-specific DNA targeting agents. These include synthetic polyamides that recognize and bind to DNA in the minor groove, peptide nucleic acids which can penetrate the DNA duplex and form a P-loop, or a triple-helical structure with one of its strands, and triplehelix (triplex) forming oligonucleotides which bind to the major groove of duplex DNA at polypyrimidine / polypurine sequences. Of these, Triplex-Forming Oligonucleotides (TFOs) are the most extensively characterized synthetic ligands capable of recognizing and binding sequence specifically to duplex DNA. Consequently, they have been the focus of a new gene therapy strategy that we call ‘anti-gene radiotherapy’. This strategy employs TFOs labeled with Auger-electronemitting radionuclides to produce sequence-specific DNA double strand breaks that ultimately lead to gene inactivation following repair. Anti-gene radiotherapy is made possible by the highly localized damage produced by decay of an Augeremitter, such as 125I, and the sequence specific positioning of DNA damage made possible by TFOs. This report will address recently described strategies that employ these gene-targeting methods to alter target gene expression or structure, with particular emphasis being paid to the use of TFOs in anti-gene radiotherapy.
Keywords: gene-targeted agents, anti-gene radio therapy, triplex-forming oligonucleotide, tfos
Current Genomics
Title: Rational Drug Development Using Gene-Targeted Agents and Their Application in Anti-Gene Radiotherapy
Volume: 4 Issue: 3
Author(s): Thomas A. Winters, Elzbieta Pastwa, Kamal Datta and Ronald D. Neumann
Affiliation:
Keywords: gene-targeted agents, anti-gene radio therapy, triplex-forming oligonucleotide, tfos
Abstract: Currently rational drug design is limited to using protein targets in the design and production of therapeutic agents. However, many genetic and infectious diseases may not be adequately treated with this approach. In these circumstances the DNA sequence of an offending gene is itself a potential target for rational drug development. Genetargeted therapeutic strategies require the development of ligands that can recognize and bind unique DNA targets sequence specifically. Several approaches have been described for the development of sequence-specific DNA targeting agents. These include synthetic polyamides that recognize and bind to DNA in the minor groove, peptide nucleic acids which can penetrate the DNA duplex and form a P-loop, or a triple-helical structure with one of its strands, and triplehelix (triplex) forming oligonucleotides which bind to the major groove of duplex DNA at polypyrimidine / polypurine sequences. Of these, Triplex-Forming Oligonucleotides (TFOs) are the most extensively characterized synthetic ligands capable of recognizing and binding sequence specifically to duplex DNA. Consequently, they have been the focus of a new gene therapy strategy that we call ‘anti-gene radiotherapy’. This strategy employs TFOs labeled with Auger-electronemitting radionuclides to produce sequence-specific DNA double strand breaks that ultimately lead to gene inactivation following repair. Anti-gene radiotherapy is made possible by the highly localized damage produced by decay of an Augeremitter, such as 125I, and the sequence specific positioning of DNA damage made possible by TFOs. This report will address recently described strategies that employ these gene-targeting methods to alter target gene expression or structure, with particular emphasis being paid to the use of TFOs in anti-gene radiotherapy.
Export Options
About this article
Cite this article as:
Winters A. Thomas, Pastwa Elzbieta, Datta Kamal and Neumann D. Ronald, Rational Drug Development Using Gene-Targeted Agents and Their Application in Anti-Gene Radiotherapy, Current Genomics 2003; 4 (3) . https://dx.doi.org/10.2174/1389202033490420
DOI https://dx.doi.org/10.2174/1389202033490420 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Probiotic Research in Australia, New Zealand and the Asia-Pacific Region
Current Pharmaceutical Design Pharmacological Effect of Berberine Chloride in Propyl Thiouracil Induced Thyroidal Dysfunction - A Time Bound Study in Female Rats
Recent Patents on Drug Delivery & Formulation 13-lncRNAs Signature to Improve Diagnostic and Prognostic Prediction of Hepatocellular Carcinoma
Combinatorial Chemistry & High Throughput Screening Mitochondria and Familial Predisposition to Breast Cancer
Current Genomics Role of Chemokines and Their Receptors in Cancer
Current Pharmaceutical Design Prostaglandin E Synthase: A Novel Drug Target for Inflammation and Cancer
Current Pharmaceutical Design The Emerging Role of EMT-related lncRNAs in Therapy Resistance and their Applications as Biomarkers
Current Medicinal Chemistry Active-Targeted Nanotherapy Strategies for Prostate Cancer
Current Cancer Drug Targets Retinoids in Clinical Use
Medicinal Chemistry Effects of Tea Catechins on Inflammation-Related Cardiovascular Diseases
Current Immunology Reviews (Discontinued) Epivention: Epigenetic Based Cancer Chemoprevention
Epigenetic Diagnosis & Therapy (Discontinued) Sentinel Lymph Node Mapping in Early Stage Endometrial Cancer Patients in Low-Resource Settings
Current Women`s Health Reviews Cancer Microbiome; Opportunities and Challenges
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapeutic Strategies for Targeting BRAF in Human Cancer
Reviews on Recent Clinical Trials Positron Emitting Tracers in Pre-Clinical Drug Development
Current Radiopharmaceuticals Analysis of Capsaicinoids in Hot Sauces Using a Silica Hydride-Based Stationary Phase
Current Chromatography Hedgehog Signaling and Urological Cancers
Current Drug Targets Transactivation of EGFR by G Protein-Coupled Receptor in the Pathophysiology of Intimal Hyperplasia
Current Vascular Pharmacology Roles of Natural Compounds from Medicinal Plants in Cancer Treatment: Structure and Mode of Action at Molecular Level
Medicinal Chemistry Enrichment of Up-regulated and Down-regulated Gene Clusters Using Gene Ontology, miRNAs and lncRNAs in Colorectal Cancer
Combinatorial Chemistry & High Throughput Screening